NEW YORK (Reuters Health) Oct 18 –
Bristol-Myers Squibb Co.’s antibiotic Tequin (gatifloxacin) has received an additional US approval as a treatment for uncomplicated skin and skin structure infections, the US Food and Drug Administration (FDA) said on Friday.
Tequin was first approved in the US in December 1999 as a treatment for respiratory infections, and has been subsequently cleared for other indications including urinary tract infections and gonorrhea.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!